Unblocking the CAR-T supply chain
As part of serum replacement, high quality recombinant Human Insulin can improve T Cell expansion and in-vivo function in CAR-T therapy optimization.
Transfer of T Cells genetically modified to target cancer cell antigens (CAR-T therapy) is a promising oncology treatment strategy. The big challenge remains to scale-up the manufacturing process, improve consistency and reduce the costs.
One of the main current limiting factors in the manufacturing process is dependency on human serum, which is used to support T lymphocyte growth and survival when cultured ex-vivo.
Human serum is expensive and the current supply chain will not meet the demands when different approved CAR-T therapies become blockbuster treatments. High focus on T-Cell media development has recently allowed several serum free media being introduced on the market, with different proprietary formulation based on key components, such as human insulin.
This is a particularly relevant development for people working in upstream bio manufacturing, R&D, BD and any stakeholder involved in cell line and media development, cell and gene therapy manufacturing who are focused on bioprocess optimization, high cell viability and high productivity.
The text is created in collaboration with Pharmaceutical Networking.